Profiles of Serial Changes in Cardiac Troponin T Concentrations and Outcome in Ambulatory Patients With Chronic Heart Failure

Journal of the American College of Cardiology

Volumn 54, Issue 18, 2009, Pages 1715-1721

  Miller, Wayne L ^a   Hartman, Karen A ^a   Burritt, Mary F ^a   Grill, Diane E ^a   Jaffe, Allan S ^a  

^a MAYO CLINIC   (United States)

Author keywords

chronic heart failure; outcomes; outpatients; troponin T

Indexed keywords

TROPONIN T;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS;

AGED; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; OFFICE VISITS; OUTPATIENTS; PROGNOSIS; PROSPECTIVE STUDIES; STROKE VOLUME; TROPONIN T; VENTRICULAR FUNCTION, LEFT;

EID: 70349983577     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.07.025     Document Type: Article

References (32)

1. McMurray J., Cohen-Solal A., Dietz R., et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail 7 (2005) 710-721
2. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004) 2140-2150
3. Konstam M.A. Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol 96 (2005) 867-871
4. Davila D.F., Nunez T.J., Oderman R., and Mazzei de Davila C.A. Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications. Int J Cardiol 101 (2005) 343-346
5. Wong M., Staszewsky L., Latini R., et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan Heart Failure Trial echocardiographic data. J Am Coll Cardiol 43 (2004) 2022-2027
6. Perna E.R., Macin S.M., Cimbaro Canella J.P., et al. Ongoing myocardial injury in stable severe heart failure. Value of cardiac troponin T monitoring for high-risk patient identification. Circulation 110 (2004) 2376-2382
7. Sato Y., Yamada T., Taniguchi R., et al. Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 103 (2001) 369-374
8. Sato Y., Kita T., Takatsu Y., and Kimura T. Biochemical markers of myocyte injury in heart failure. Heart 90 (2004) 1110-1113
9. Ishii J., Nomura M., Nakamura Y., et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 89 (2002) 691-695
10. Yan R.T., White M., Yan A.T., et al. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol 96 (2005) 698-704
11. Miller W.L., Hartman K.A., Burritt M.F., et al. Serial biomarker measurements in ambulatory patients with chronic heart failure. The importance of change over time. Circulation 116 (2007) 249-257
12. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial Infarction Redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 36 (2000) 959-969
13. Apple F.S., Wu A.H.B., and Jaffe A.S. Guidelines for redefinition of myocardial infarction. How to use existing assays clinically and for clinical trials. Am Heart J 144 (2002) 981-986
14. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
15. Therneau T.M., and Grambsch P.M. Modeling Survival Data: Extending the Cox Model (2000), Springer-Verlag, New York, NY
16. Healey J.S., Davies R.F., Smith S.J., Davies R.A., and Ooi D.S. Prognostic use of cardiac troponin T and troponin I in patients with heart failure. Can J Cardiol 19 (2003) 383-386
17. Horwich T.B., Patel J., MacLellan R., and Fonarow G.C. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 108 (2003) 833-838
18. Hudson M.P., O'Connor C.M., Gattis W.A., et al. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am Heart J 147 (2004) 546-552
19. Perna E.R., Macin S.M.C., et al. High levels of troponin T are associated with ventricular remodeling and adverse in-hospital outcome in heart failure. Med Sci Monit 10 (2004) CR90-CR95
20. Cleland J.G., Swedberg K., Follath F., et al. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 24 (2003) 442-463
21. Adams Jr. K.F., Fonarow G.C., Emerman C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 (2005) 209-216
22. Gheorghiade M., Stough W.G., Adams Jr. K.F., Jaffe A.S., Hasselblad V., and O'Connor C.M. The pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF). Am J Cardiol 96 Suppl 1 (2005) 18-25
23. Narula J., Haider N., Virmani R., et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335 (1996) 1182-1189
24. Troughton R.W., Framptom C.M., Yaandle T.G., et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
25. Jourdain P.J., Jondeau G., Funck F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure. J Am Coll Cardiol 49 (2007) 1733-1739
26. Richards M., Lainchbury J.G., Troughton R.W., et al. NT-ProBNP Guided Treatment for Chronic Heart Failure: results from the BATTLESCARRED trial. Circulation 118 (2008) S1035-S1036
27. Pfisterer M., Buser P., Ricki H., et al. BNP-guided vs. symptom-guided heart failure therapy. The Trial of Intensified vs. Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301 (2009) 383-392
28. Miller W.L., Hartman K.A., Grill D.E., Burnett J.C., and Jaffe A.S. Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcomes in ambulatory patients with chronic heart failure. Clin Chem 55 (2009) 78-84
29. Miller W.L., Hartman K.A., Burritt M.F., Burnett J.C., and Jaffe A.S. Troponin, B-type natriuretic peptide levels and outcomes in patients with severe heart failure: differences between ischemic and idiopathic dilated cardiomyopathies. Clin Cardiol 30 (2007) 245-250
30. Wencker D., Chandra M., Nguyen K., et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 111 (2003) 1497-1504
31. Foo R.S.-Y., Mani K., and Kitsis R.N. Death begets failure in the heart. J Clin Invest 115 (2005) 565-571
32. Van Kimmenade R.R.J., and Januzzi Jr. J.L. Whose heart will get broken?. Troponin testing and future heart failure. Eur Heart J 30 (2009) 755-756